ERAS Investors Have Opportunity to Lead Erasca, Inc. Securities Fraud Lawsuit

If you purchased Erasca, Inc. common stock between January 14, 2025 and April 26, 2026, inclusive, you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement. The important August 10, 2026 lead plaintiff deadline is approaching. According to the lawsuit, Erasca, Inc., along with its CEO and CFO, violated federal securities laws by making false and misleading statements about its lead oncology drug candidate, ERAS-0015, throughout the Class Period. According to the complaint, Erasca repeatedly touted ERAS-0015 as a potential "best-in-class" therapy and highlighted purportedly superior preclinical results compared to Revolution Medicines' competing drug candidate, RMC-6236, while failing to disclose that those comparisons were allegedly improper, exposed Erasca to patent and trade secret disputes, and lacked a reasonable basis. When the true details entered the market, the lawsuit claims that investors suffered damages.